Retatrutide is a first-in-class, investigational medication that acts as a triple agonist, targeting receptors for GLP-1, GIP, and glucagon. Early clinical data suggests this triple-action approach may lead to significant weight loss and improved metabolic health.
Classification: Triple GIP/GLP-1/Glucagon receptor agonist (first in class). Half-Life Extension: Fatty acid modification enabling albumin binding for extended research duration. Receptor Targets: GIP receptor (full agonism), GLP-1 receptor (agonism), Glucagon receptor (agonism).
Triple agonist therapy works by targeting multiple systems at once instead of just targeting one pathway through the hormone receptor system, unlike most conventional methods. It allows a more complete metabolic response compared to previously available methods.
Triple agonists are investigational but advancing rapidly: retatrutide and survodutide are both in Phase 3 trials with efficacy data suggesting they will become first-line obesity pharmacotherapy within this decade. The receptor targets, metabolic pathways...
Among these, triple agonists targeting GLP-1, GIP, and glucagon receptors represent a promising next step. This review outlines the rationale for their development and summarizes clinical trial data, focusing on retatrutide, the most advanced candidate.
Furthermore, visual representations like the one above help us fully grasp the concept of A Triple Agonist Targeting.
Retatrutide peptide (LY3437943) is a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously making it the most potent weight loss compound in clinical development.
The triple agonist approach theoretically provides more comprehensive metabolic targeting, though the clinical significance of added glucagon agonism requires validation in Phase 3 trials.
Retatrutide is a triple agonist, activating the GIP and GLP-1 receptors plus a third target: the glucagon receptor (GCGR). This additional mechanism of action is hypothesized to increase energy expenditure, contributing to the greater weight loss observed in...
